青泽强

目的：探究社区全科治疗原发性高血压的临床效果。方法：选取在2022年4月到2025年4月本社区收治的70例原发性高血压患者，随机数字表法分为观察组（社区全科治疗）、对照组（常规治疗）各35人。对比治疗效果，血压及生活质量状况。结果：相比对照组，观察组治疗效果较高（P<0.05）；治疗后，观察组血压水平较低、生活质量评分均较高（P<0.05）。结论：社区全科治疗原发性高血压的治疗效果更高，能够有效控制患者的血压水平，提升其生活质量。

社区全科治疗；原发性高血压；临床效果

[1] 刘春丽.原发性高血压患者应用社区全科治疗的效果观察[J].智慧健康,2022,8(33):24-28. [2] 张锦访.社区全科门诊采用苯磺酸氨氯地平治疗原发性高血压的效果观察[J].黑龙江中医药,2023,52(4):162-164. [3] 杨淼,毛玲鹰.社区全科治疗原发性高血压的临床效果[J].名医,2023(22):42-44. [4] 黄旭峰.全科医学治疗模式在社区原发性高血压患者治疗中的应用价值[J].医学食疗与健康,2023,21(31):283-284,293. [5] 张建城.原发性高血压在社区进行全科治疗的效果分析[J].健康之友,2023(23):72-74. [6] 周震,刘海燕,李帅德,等.全科医生签约服务在社区原发性高血压患者管理中的应用效果[J].中国社区医师,2024,40(19):148-150. [7] 龚京冬.社区全科门诊应用苯磺酸氨氯地平治疗原发性高血压的临床价值[J].养生保健指南,2022(25):17-20. [8] 刘斌.艾司唑仑联合缬沙坦､依那普利治疗原发性高血压的应用效果及对外周血管阻力影响[J].现代诊断与治疗,2024,35(3):368-370. [9] 林木森.观察氨氯地平贝那普利联合美托洛尔治疗原发性高血压患者的临床效果[J].黑龙江医药,2024,37(4):822-824. [10] 陈荔萍,金迎,魏魏.社区原发性高血压患者的健康自我倾注和对原发性高血压病认识的定性调查[J].中华全科医师杂志, 2022,21(10):923-929. [29] Koupenova M,Clancy L,Corkrey H A,et al.Circulating Platelets as Mediators of Immunity,Inflammation,and Thrombosis[J]. Circulation Research,2018,122(2):337-351. [30] Puertas M,Zayas-Castro J L,Fabri P J.Statistical and prognostic analysis of dynamic changes of platelet count in ICU patients[J]. Physiological Measurement,2015,36(5):939-953. [31] Pinna A,Carlino P,Serra R,et al.Red Cell Distribution Width(RDW)and Complete Blood Cell Count-Derived Measures in Non- Arteritic Anterior Ischemic Optic Neuropathy[J].International Journal of Medical Sciences,2021,18(10):2239-2244. [32] Park B J,Shim J Y,Lee H R,et al.The relationship of platelet count,mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists:a focus on gender differences[J].Platelets,2012,23(1):45-50. [33] Yang K,Du C,Wang X,et al.Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice[J].Blood,2017,129(19):2667-2679. [34] G L,M S,M P,et al.Mean platelet volume predicts vascular access events in hemodialysis patients[J].Journal of clinical medicine, 2019,8(5). [35] Catanzaro R,Sciuto M,Lanzafame C,et al.Platelet to lymphocyte ratio as a predictive biomarker of liver fibrosis(on elastography)in patients with hepatitis C virus(HCV)-related liver disease[J].Indian Journal of Gastroenterology:Official Journal of the Indian Society of Gastroenterology,2020,39(3):253-260. [36] Kumarasamy C,Tiwary V,Sunil K,et al.Prognostic Utility of Platelet-Lymphocyte Ratio,Neutrophil-Lymphocyte Ratio and Monocyte- Lymphocyte Ratio in Head and Neck Cancers:A Detailed PRISMA Compliant Systematic Review and Meta-Analysis[J].Cancers, 2021,13(16):4166. [37] Gan W,Guan Q,Hu X,et al.The association between platelet-lymphocyte ratio and the risk of all-cause mortality in chronic kidney disease:a systematic review and meta-analysis[J].International Urology and Nephrology,2022,54(11):2959-2967. [38] Binnetoğlu E,Şengül E,HalhallıG,et al.Is neutrophil lymphocyte ratio an indicator for proteinuria in chronic kidney disease?[J].Journal of Clinical Laboratory Analysis,2014,28(6):487-492. [39] Li Q,Chen P,Shi S,et al.Neutrophil-to-lymphocyte ratio as an independent inflammatory indicator of poor prognosis in IgA nephropathy[J].International Immunopharmacology,2020,87:106811. [40] Duan S,Sun L,Zhang C,et al.Association of platelet-to-lymphocyte ratio with kidney clinicopathologic features and renal outcomes in patients with diabetic kidney disease[J].International Immunopharmacology,2021,93:107413. [41] Rayego-Mateos S,Morgado-Pascual J L,Opazo-Ríos L,et al.Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy[J].International Journal of Molecular Sciences,2020,21(11):3798. [42] Yuan Q,Tang B,Zhang C.Signaling pathways of chronic kidney diseases,implications for therapeutics[J].Signal Transduction and Targeted Therapy,2022,7(1):182. [43] Sato Y,Mii A,Hamazaki Y,et al.Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney[J].JCI insight,2016,1(11):e87680. [44] Bartnicki P.Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease[J].Biomedicines,2024,12(8):1884. [45] Ueda N,Takasawa K.Impact of Inflammation on Ferritin,Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease[J].Nutrients,2018,10(9):1173. [46] Mandel J,Casari M,Stepanyan M,et al.Beyond Hemostasis:Platelet Innate Immune Interactions and Thromboinflammation[J]. International Journal of Molecular Sciences,2022,23(7):3868. [47] Papayannopoulos V.Neutrophil extracellular traps in immunity and disease[J].Nature Reviews Immunology,2018,18(2):134-147. [48] Wang N,Tall A R.Cholesterol in platelet biogenesis and activation[J].Blood,2016,127(16):1949-1953.

点击下载PDF